{"id":684981,"date":"2022-09-14T05:48:45","date_gmt":"2022-09-14T09:48:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/"},"modified":"2022-09-14T05:48:45","modified_gmt":"2022-09-14T09:48:45","slug":"shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/","title":{"rendered":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 – (NASDAQ: HGEN)"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NEW YORK<\/span>
\n <\/span>, Sept. 14, 2022<\/span><\/span> \/PRNewswire\/ — The Gross Law Firm issues the following notice to shareholders of Humanigen, Inc..<\/b><\/p>\n

Shareholders who purchased shares of HGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n

CONTACT US HERE:<\/p>\n

\n https:\/\/securitiesclasslaw.com\/securities\/humanigen-inc-loss-submission-form\/?id=31654&from=4<\/a>\n <\/p>\n

\n CLASS PERIOD: <\/b>
\n May 28, 2021<\/span> to July 12, 2022<\/span><\/p>\n

\n ALLEGATIONS: <\/b>The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) Humanigen’s lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5\/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab’s clinical and commercial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.<\/p>\n

\n DEADLINE: October 25, 2022<\/span><\/b> Shareholders should not delay in registering for this class action. Register your information here: https:\/\/securitiesclasslaw.com\/securities\/humanigen-inc-loss-submission-form\/?id=31654&from=4<\/a><\/p>\n

\n NEXT STEPS FOR SHAREHOLDERS: <\/b>Once you register as a shareholder who purchased shares of HGEN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is October 25, 2022<\/span>. There is no cost or obligation to you to participate in this case.<\/p>\n

\n WHY GROSS LAW FIRM? <\/b>The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

\n CONTACT:<\/b>
\n
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY<\/span>, 10018
Email: dg@securitiesclasslaw.com<\/a>
Phone: (646) 453-8903<\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022–nasdaq-hgen-301623811.html<\/a><\/p>\n

SOURCE The Gross Law Firm<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK , Sept. 14, 2022 \/PRNewswire\/ — The Gross Law Firm issues the following notice to shareholders of Humanigen, Inc.. Shareholders who purchased shares of HGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/humanigen-inc-loss-submission-form\/?id=31654&from=4 CLASS PERIOD: May 28, 2021 to July 12, 2022 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) Humanigen’s lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was … <\/p>\n

Continue reading “SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 – (NASDAQ: HGEN)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-684981","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Sept. 14, 2022 \/PRNewswire\/ — The Gross Law Firm issues the following notice to shareholders of Humanigen, Inc.. Shareholders who purchased shares of HGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/humanigen-inc-loss-submission-form\/?id=31654&from=4 CLASS PERIOD: May 28, 2021 to July 12, 2022 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) Humanigen’s lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was … Continue reading "SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 – (NASDAQ: HGEN)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-14T09:48:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY72075&sd=2022-09-14\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 – (NASDAQ: HGEN)\",\"datePublished\":\"2022-09-14T09:48:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/\"},\"wordCount\":424,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY72075&sd=2022-09-14\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/\",\"name\":\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY72075&sd=2022-09-14\",\"datePublished\":\"2022-09-14T09:48:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY72075&sd=2022-09-14\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY72075&sd=2022-09-14\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 – (NASDAQ: HGEN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN) - Market Newsdesk","og_description":"PR Newswire NEW YORK , Sept. 14, 2022 \/PRNewswire\/ — The Gross Law Firm issues the following notice to shareholders of Humanigen, Inc.. Shareholders who purchased shares of HGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/humanigen-inc-loss-submission-form\/?id=31654&from=4 CLASS PERIOD: May 28, 2021 to July 12, 2022 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) Humanigen’s lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was … Continue reading \"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 – (NASDAQ: HGEN)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-14T09:48:45+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY72075&sd=2022-09-14","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 – (NASDAQ: HGEN)","datePublished":"2022-09-14T09:48:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/"},"wordCount":424,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY72075&sd=2022-09-14","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/","name":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY72075&sd=2022-09-14","datePublished":"2022-09-14T09:48:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY72075&sd=2022-09-14","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY72075&sd=2022-09-14"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-humanigen-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-25-2022-nasdaq-hgen-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 – (NASDAQ: HGEN)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=684981"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684981\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=684981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=684981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=684981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}